Endothelial Cell Activity in Chronic Obstructive Pulmonary Disease Without Severe Pulmonary Hypertension

Abstract

Pulmonary hypertension is common in patients with chronic obstructive pulmonary disease (COPD), but the precise mechanism of vascular impairment in these patients is unknown. We, therefore, decided to investigate whether endothelial cell dysfunction is present in patients with COPD with a wide range of chronic airflow obstruction before the development of severe pulmonary hypertension. Selected plasma markers of endothelial cell activity were studied: nitrate+nitrite (NO-₂/NO-₃), thrombomodulin (TM), tissue factor pathway inhibitor (TFPI), soluble selectins (endothelium sES, leukocyte sLS, platelet sPS), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1). Twenty-five patients with COPD (forced expiratory volume in one second/vital capacity [FEV₁/VC] < 88% predicted) and 29 healthy control subjects were recruited to the study. Among patients nine had a pulmonary artery systolic pressure (PASP) between 15 and 30 mmHg, 13 between 32 and 38 mmHg, 2 had a PASP of 41 and 42 mmHg, respectively. One patient had severe pulmonary hypertension with a PASP of 70 mmHg. The average FEV₁ of patients with COPD was 46 ± 4% predicted. As compared to control subjects, patients with COPD showed a significant increase in plasma levels of TM and TFPI, indicating that their endothelial cells are still able to produce potent coagulation inhibitors. Levels of NO-₂/NO-₃were similar in the two groups of subjects examined, further suggesting preserved endothelial function in patients with COPD. In regard to adhesion molecules, patients with COPD showed a reduction in sLS, sPS, and sPECAM-1, and an increase in sICAM-1. This study shows that endothelial cell activity is largely preserved in patients with COPD without severe pulmonary hypertension, suggesting that these patients, despite quite severe airway obstruction, retain reasonably normal endothelial function until they develop severe pulmonary hypertension.

Keywords

Chronic obstructive pulmonary disease Pulmonary hypertension Nitric oxide Thrombomodulin Tissue factor pathway inhibitor Selectins

References

Barberà JA , Peinado VI , Santos S. Pulmonary hypertension in COPD: Old and new concepts. Monaldi Arch Chest Dis 2000;55:445.

Hale KA , Niewoehner DE , Cosio MG . Morphologic changes in the muscular pulmonary arteries: Relationship to cigarette smoking, airway disease and emphysema. Am Rev Resp Dis 1980;122:273.

Mitchell RS , Silver GW , Det GA , et al. Clinical and morphologic complications in chronic airways obstructions. Am Rev Resp Dis 1968;97:54.

Cines DB , Pollak ES , Buck CA , et al. Endothelial cells in physiology and in pathopysiology of vascular disorders. Blood 1998;91:3527.

Moraes D , Loscalzo J. Pulmonary hypertension: New concepts in diagnosis and management. Clin Cardiol 1997;20:676.

Cella G , Bellotto F , Tona F , et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001;120:1226.

Siafakas NM , Vermeire P , Pride NB , et al. on behalf of the Task force Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society. Eur Resp J 1995;8:1398.

McQuillan BM , Picard MH , Leavit M , et al. Clinical correlate and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797.

Saetta M , Di Stefano A , Maestrelli P , et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Resp Crit Care Med 1994;150:1646.

10.

Nims RW , Cook JC , Krishna MC , et al. Colorimetric assay for nitric oxide and nitric oxide species formed from nit oxide stock solutions and donor compounds. Methods Enzymol 1996;268:93.

11.

Dinh-Xuan AT , Higenbottam TW , Clelland CA , et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive pulmonary disease. N Engl J Med 1991;324:1539.

12.

Peinado VI , Barbera JA , Ramiraz J , et al. Endothelial dysfunction in pulmonary arteries with mild COPD. Am J Physiol 1998;274:L908.

13.

Alessandri C , Basili S , Violi F , et al , and C.O.B-H Group . Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994;72:343.

14.

Davì G , Basili S , Vieri M , et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. Am J Resp Crit Car Med 1997;156:1794.

15.

Bombeli T , Muller M , Haeberli A. Anticoagulant property of the vascular endothelium. Thromb Haemost 1997;77:408.

16.

Bajaj MS , Briktoft JJ , Steer SA , Bajaj SP . Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959.

17.

Rosenberg RD . Vascular-bed-specific hemostasis and hypercoagulable states: Clinical utility of activation peptide assay in predicting thrombotic events in different clinical populations. Thromb Haemost 2001;86:41.

18.

Salomaa V , Matei C , Aleksic N , et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study. Lancet 1999;353:1729.

19.

Cella G , Randi ML . Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet 1999;354:425.

20.

Cacub P , Karmochkine M , Dorent R , et al. Plasma levels of thrombomodulin in pulmaonary hypertension. Am J Med 1996;101:160.

21.

Altieri DC . Leukocyte interaction with protein cascades in blood coagulation. Curr Opin Hematol 1995;2:41.

22.

McEver RP . Adhesive interactions of leukocytes, platelets and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746.

23.

Loscalzo J. Nitic oxide insufficiency, platelet activation and arterial thrombosis. Circ Res 2001;88:756.

24.

Pilewski JM , Albelda SM . Adhesion molecules in the lung: An overview. Am Rev Resp Dis 1993;148:S31.

25.

Tomassini JE , Graham D , DeWitt CM , et al. CDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intracellular adhesion molecule-1. Proc Nat Acad Sci USA 1989;86:4907.

26.

Tosi M , Stark J , Hamdani A , et al. Intercellular adhesion molecule-1 (ICAM-1) dependent and ICAM-1 independent adhesive interactions between polymorphonuclear leukocytes and human airway epithelial cells infected with parainfluenza virus type 2. J Immunol 1992;149:3345.

27.

Papi A , Johnston SL . Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kB mediated trancription. J Biol Chem 1999;274:9707.

28.

Di Stefano A , Maestrelli P , Roggeri A , et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Resp Crit Care Med 1994;149:803.

29.

Vignola AM , Campbell AM , Chanez P , et al. HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis. Am Rev Resp Dis 1993;148:689.

30.

Riise GC , Larsson S , Lofdhal CG , et al. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Resp J 1994;7:1673.